Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS

NCT03894215 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT03894215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03894215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Lead sponsor
Agenus Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2019
Completion date
March 26, 2025
Enrollment
211 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer